US 7632503
Method of treating a muscle-related condition with modified IGF1 polypeptides
granted A61KA61K38/00
Quick answer
US patent 7632503 (Method of treating a muscle-related condition with modified IGF1 polypeptides) held by REGENERON PHARMACEUTICALS, INC. expires Mon Dec 10 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Dec 15 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 10 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 2
- CPC classes
- A61K, A61K38/00